HOUSTON, Aug. 10, 2006 (PRIMEZONE) -- Encysive Pharmaceuticals (Nasdaq:ENCY) was notified today that the European Commission has adopted the decision granting marketing authorization for THELIN(r)(1) (sitaxentan sodium(2)) in the European Union. The Company is awaiting the formal decision letter from the European Commission. Following receipt, which is expected soon, the Company will provide further information.
